In AML with mutations in NPM1 (encoding nucleophosmin), I-BET151 abrogates the HOX-independent transcription program [75], and represses the MYC-dependent program in myeloma, leading to strong antiproliferative effect in vitro and in vivo [76]. The gene discussed is MYC; the disease is plasma cell myeloma.